### Guideline Page and Request

**COL-C/REC-E**

1 of 9

2 of 9

3 of 9

Internal/External request: Consider the continuation of bevacizumab in combination with chemotherapy as a second-line treatment in patients with mCRC who progressed after receiving bevacizumab in combination with chemotherapy in the first-line setting.

### Panel Discussion

Based upon the data in the noted reference, the panel consensus was to add bevacizumab to chemotherapy for the following indications:

- Therapy after first progression on oxaliplatin-based therapy
  - “± bevacizumab” added to FOLFIRI and irinotecan.
- Therapy after first progression on irinotecan-based therapy: “± bevacizumab” added to FOLFOX and CapeOx.
- Therapy after first progression on fluoropyrimidine-based therapy
  - “± bevacizumab” added to FOLFOX, CapeOx, FOLFIRI, irinotecan, and irinotecan + oxaliplatin.

### References

Arnold D, Andre T, Bennouna J, et al. Bevacizumab (Bev) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with Bev + CT: results of a randomized Phase III intergroup study – TML (ML18147). Presented at the American Society of Clinical Oncology 2012 Annual Meeting in Chicago, IL; June 1-5, 2012. ASCO Abstract #CRA3503. Available at: [http://meeting.ascopubs.org/cgi/content/abstract/30/18_suppl/CRA3503](http://meeting.ascopubs.org/cgi/content/abstract/30/18_suppl/CRA3503)

### Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
### Panel Discussion

Based upon the data in the noted reference, the panel consensus was to add ziv-aflibercept to chemotherapy for the following indications:

- **Therapy after first progression on oxaliplatin-based therapy**
  - FOLFIRI ± ziv-aflibercept added as a treatment option.
  - Irinotecan ± ziv-aflibercept added as a treatment option.

- **Therapy after first progression on fluoropyrimidine-based therapy**
  - FOLFIRI ± ziv-aflibercept added as a treatment option.
  - Irinotecan ± ziv-aflibercept added as a treatment option.

### References

Allegra CJ, Lakomy R, Tabernero J, et al. Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen [abstract]. J Clin Oncol 2012;30 (suppl.):3505. Available at: http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/3505

### Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>